Most nootropic compounds target a single neurotransmitter system — a serotonin reuptake inhibitor here, a dopamine precursor there. Nootropic peptides don’t work that way. The most-studied cognitive peptides operate upstream, modulating neurotrophin expression, receptor sensitivity, and neural oscillation patterns simultaneously. This page covers the three most-researched nootropic peptides in the current literature: Selank, Semax, and DSIP.
All content on this page is for informational and educational purposes only. These compounds are research chemicals, not approved for human use in the United States. Nothing here constitutes medical advice.
What Are Nootropic Peptides?
Nootropic peptides are short amino acid chains that cross or influence the blood-brain barrier and produce measurable changes in cognition, mood, stress response, or sleep architecture. Unlike synthetic small-molecule nootropics (racetams, ampakines), peptides interact with endogenous receptor systems and neurotrophin pathways the brain already uses. This gives them a different side-effect profile and a different mechanism ceiling.
The three peptides below represent distinct categories of cognitive intervention: anxiolytic/anti-stress modulation (Selank), neurotrophin upregulation (Semax), and sleep-cycle optimization (DSIP). They’re sometimes stacked; they’re more often studied alone.
Selank — Anxiolytic Activity Without Benzodiazepine Dependency
Selank is a synthetic heptapeptide analogue of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg). Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it received clinical approval in Russia in 2009 for generalized anxiety disorder and neurasthenia. That’s not a footnote — it’s a meaningful data point. Selank has been in regulated clinical use for over 15 years.
Mechanism of Action
- GABAergic modulation: Selank enhances GABA-A receptor sensitivity without direct agonism at the benzodiazepine binding site, which is why it doesn’t produce tolerance or physical dependence at the same rate as classical benzos.
- BDNF upregulation: Selank has been shown in preclinical studies to increase brain-derived neurotrophic factor expression in the hippocampus and prefrontal cortex — brain regions central to learning and working memory.
- Serotonin metabolism: Selank increases activity of serotonin-metabolizing enzymes, particularly MAO-A in the brainstem. This isn’t simple serotonin boosting — it’s modulation of turnover rate, which affects both mood baseline and stress reactivity.
- Alpha wave normalization: EEG studies in anxious subjects show Selank increases alpha wave power in frontal and parietal regions — the same neural signature seen after successful anxiolytic treatment, associated with calm alertness rather than sedation.
Key Research Findings
A 2008 study by Semenova et al. compared Selank to medazepam (a classical benzodiazepine) in an experimental anxiety model. Selank produced comparable anxiolytic effects but without the motor impairment and sedation. A 2012 Meshalkina et al. study demonstrated Selank’s ability to normalize stress-induced disruption of memory consolidation in rats, an effect blocked by GABA-A antagonists, confirming GABAergic involvement.
Critically: Selank does not suppress the hypothalamic-pituitary-adrenal (HPA) axis the way corticosteroids or heavy sedatives do. Subjects remain cognitively functional. This is the key distinction from benzodiazepine class compounds in the research literature.
→ See the full Selank research profile
Semax — BDNF at 300–800%, Derived from ACTH 4-10
Semax is a synthetic heptapeptide based on the ACTH 4-7 sequence (Met-Glu-His-Phe) with a Pro-Gly-Pro C-terminal extension. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside Selank and has been approved in Russia for cognitive impairment, ischemic stroke recovery, and optic nerve disease since the mid-1990s. Its primary mechanism of interest is neurotrophin upregulation — specifically BDNF and NGF.
Mechanism of Action
- BDNF induction (300–800%): Multiple preclinical studies have documented Semax increasing hippocampal BDNF mRNA expression by 300–800% within hours of administration. BDNF (brain-derived neurotrophic factor) supports synaptic plasticity, long-term potentiation, and neuronal survival. This is the most cited mechanism in the Semax literature.
- NGF upregulation: Semax also elevates nerve growth factor (NGF) in the basal forebrain — a region with heavy cholinergic innervation critical for attention and episodic memory. NGF deficiency is a consistent finding in Alzheimer’s pathology.
- ACTH 4-10 peptide family: Semax is derived from the ACTH 4-10 region, which is the behaviorally active fragment of adrenocorticotropin. Critically, Semax has been modified so it does not trigger cortisol release — the adrenal axis component is stripped. You get the cognitive enhancement signal (neuroprotection, attention, stress resilience) without the glucocorticoid burden.
- Dopaminergic and serotonergic activity: Semax increases dopamine and serotonin turnover in the striatum and prefrontal cortex. The effect is modulatory rather than stimulant-like — no significant locomotor activation seen in preclinical models at therapeutic doses.
Key Research Findings
A landmark 1999 study by Dolotov et al. documented Semax-induced BDNF mRNA upregulation in rat hippocampus. A 2003 study by Grivennikov et al. confirmed the NGF component and its relation to cholinergic system function. Clinical studies in ischemic stroke patients (Semax is approved for this indication) show improved neurological outcome scores versus control, attributed to neuroprotective and neurotrophic mechanisms rather than vascular effects.
The N-Acetyl Semax and N-Acetyl Semax Amidate variants have gained attention in recent research for potentially extended half-life and enhanced CNS penetration compared to unmodified Semax, though direct head-to-head data is limited.
→ See the full Semax research profile
DSIP — Delta Sleep Without REM Suppression
Delta Sleep-Inducing Peptide (DSIP) is a nine-amino-acid neuropeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1974 from the cerebral venous blood of rabbits in slow-wave sleep. It’s naturally present in the human hypothalamus, pituitary, and peripheral tissues including the gut and adrenal glands. The research focus is sleep architecture modulation and cortisol rhythm normalization.
Mechanism of Action
- Slow-wave sleep (SWS) promotion: DSIP promotes delta wave activity during non-REM sleep — specifically Stage 3 (slow-wave) sleep. This is the deepest, most restorative sleep stage, associated with growth hormone secretion, memory consolidation, and tissue repair. Crucially, it does this without suppressing REM sleep, unlike most sedative compounds including benzodiazepines and non-benzo sleep aids (Z-drugs).
- Cortisol modulation: DSIP has been shown to normalize dysregulated cortisol secretion — reducing elevated cortisol in hypercortisolemic subjects while not significantly suppressing normal cortisol levels. This bidirectional, normalizing effect on the stress hormone axis is why DSIP research is relevant to both sleep quality and stress physiology simultaneously.
- LH and GH interaction: DSIP influences luteinizing hormone (LH) and growth hormone (GH) pulsatility, consistent with its broad role in circadian/pulsatile hormone regulation. GH is released predominantly during SWS — DSIP’s enhancement of SWS duration has downstream effects on GH secretion.
- Opioid and monoamine interaction: DSIP modulates mu-opioid receptor sensitivity and has effects on noradrenergic signaling, which may explain additional anxiolytic and analgesic effects observed in some models beyond the core sleep mechanism.
Key Research Findings
The original Monnier et al. (1977) characterization established DSIP as a genuine sleep-inducing factor. Subsequent work by Graf and colleagues in the 1980s-90s examined DSIP in chronic insomnia patients, showing reduced sleep latency and increased slow-wave sleep duration without next-day impairment. The cortisol-modulating properties were explored by Kastin and colleagues. More recent interest has focused on DSIP’s potential role in stress-related sleep disruption, where the dual sleep/cortisol mechanism is particularly relevant.
DSIP’s short half-life in plasma (under 30 minutes) has led to research interest in analogues with improved stability, though native DSIP remains the most-studied form.
→ See the full DSIP research profile
Nootropic Peptide Comparison
| Peptide | Primary Mechanism | Key Effect | Regulatory Status | Research Volume |
|---|---|---|---|---|
| Selank | GABAergic + BDNF + serotonin metabolism | Anxiolytic, stress resilience, alpha wave normalization | Approved (Russia, 2009) — anxiety/neurasthenia | High (30+ studies) |
| Semax | BDNF/NGF upregulation, ACTH 4-10 derived | Neuroplasticity, neuroprotection, attention | Approved (Russia, 1995) — stroke, cognitive impairment | High (50+ studies) |
| DSIP | Delta wave promotion, cortisol normalization | SWS enhancement, sleep architecture optimization | Research compound — no clinical approval | Moderate (20+ studies) |
Explore Individual Peptide Profiles
- Selank — Full Research Profile
- Semax — Full Research Profile
- DSIP — Full Research Profile
- Browse All Peptides Available for Research
Research Disclaimer: All peptides listed on this site are intended for laboratory research purposes only. They are not approved by the FDA for human use, diagnosis, treatment, or prevention of any condition. Information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before considering any peptide compound. NoProp Peptides does not condone or encourage self-administration of research chemicals.